Natera to Present 12 Datasets Featuring Over 50,000 Patients at SABCS 2025
ByAinvest
Tuesday, Dec 2, 2025 8:12 am ET1min read
NTRA--
Natera will present 12 abstracts at the San Antonio Breast Cancer Symposium featuring data from over 50,000 patients using Signatera, a genome-based test for breast cancer recurrence. The data demonstrates 100% sensitivity and specificity in detecting breast cancer recurrence in the surveillance setting, with patients who tested positive for Signatera at any time post-treatment associated with worse distant recurrence-free survival. The presentations showcase the prognostic and predictive power of Signatera across diverse breast cancer subtypes and settings.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet